Title: Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3 Year Outcome
Abstract: Objectives:The purpose of this study was to report the functional and anatomical results of intravitreal ranibizumab (IVR) injections administered for myopic choroidal neovascularization (mCNV) secondary to pathological myopia.Methods: In this retrospective study, 32 eyes of 32 mCNV patients were evaluated.After a first IVR injection, patients were followed up and treated with an as-needed monthly regime.Best-corrected visual acuity and optic coherence tomography (OCT) findings were evaluated at baseline and then monthly.The reinjection criteria were a reduction in visual acuity and/or an increase in central macular thickness measured with OCT.Results: The mean age of the patients was 57.7±14.6 years, and the mean axial length was 27.8±1.3mm.The mean visual acuity improved significantly from 46.4±9.7 letters at baseline to 54.1±9.5 letters at the last follow-up visit (p<0.05).The mean central macular thickness decreased from 301.4±11.7 μm at baseline to 258.8±12.5 μm at the last visit (p>0.05).The mean number of injections was 3.5±1.1,2.3±0.9, and 1.7±0.8, at 12, 24, and 36 months, respectively. Conclusion:The results of this study indicated that IVR injections provided a significant long-term visual and anatomical benefit in cases of mCNV with few injections.